Published in Fertil Steril on April 11, 2009
Serum parathyroid hormone concentrations are increased in women with polycystic ovary syndrome. Clin Chem (2005) 1.62
Comparative study of plasma ghrelin levels in women with polycystic ovary syndrome, in hyperandrogenic women and in normal controls. Hum Reprod (2005) 1.43
The alpha2B adrenergic receptor deletion/insertion polymorphism in morbid obesity. Clin Auton Res (2003) 1.43
Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels. Am J Physiol Endocrinol Metab (2008) 1.27
Endocrine disruptors and polycystic ovary syndrome (PCOS): elevated serum levels of bisphenol A in women with PCOS. J Clin Endocrinol Metab (2010) 1.24
Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS. Clin Endocrinol (Oxf) (2007) 1.18
Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod (2006) 1.10
Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study. Hum Reprod (2011) 1.00
Identification of iodine deficiency in the field by the rapid urinary iodide test: comparison with the classic Sandell-Kolthoff reaction method. Thyroid (2002) 0.97
Polycystic ovary syndrome: the influence of environmental and genetic factors. Hormones (Athens) (2006) 0.95
Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) (2008) 0.93
Serum concentrations of carboxylated osteocalcin are increased and associated with several components of the polycystic ovarian syndrome. J Bone Miner Metab (2010) 0.93
Measurement of salivary resistin, visfatin and adiponectin levels. Peptides (2011) 0.91
Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochem Cell Biol (2007) 0.90
The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia. Gynecol Endocrinol (2010) 0.90
Creatine phosphokinase in ectopic pregnancy revisited: significant diagnostic value of its MB and MM isoenzyme fractions. Am J Obstet Gynecol (2006) 0.89
Endocrine disorders in adolescent and young female athletes: impact on growth, menstrual cycles, and bone mass acquisition. J Clin Endocrinol Metab (2014) 0.89
Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels. Fertil Steril (2007) 0.89
Anti-mullerian hormone is associated with advanced glycosylated end products in lean women with polycystic ovary syndrome. Eur J Endocrinol (2009) 0.89
Functional significance of the thyrotropin receptor germline polymorphism D727E. Biochem Biophys Res Commun (2003) 0.89
Effect of the interval between pregnancies on the health of mother and child. Eur J Obstet Gynecol Reprod Biol (2002) 0.88
Lipid and lipoprotein profile in women with polycystic ovary syndrome. Can J Physiol Pharmacol (2008) 0.87
Receiver operator characteristics and diagnostic value of progesterone and CA-125 in the prediction of ectopic and abortive intrauterine gestations. Eur J Obstet Gynecol Reprod Biol (2005) 0.87
The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome. Endocr J (2011) 0.86
The clinical significance of anti-Müllerian hormone evaluation in gynecological endocrinology. Hormones (Athens) (2011) 0.86
Phenotypic expression, body mass index and insulin resistance in relation to LH levels in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol (2011) 0.85
Genetic variants in TCF7L2 and KCNJ11 genes in a Greek population with polycystic ovary syndrome. Gynecol Endocrinol (2008) 0.85
Plasma visfatin levels in normal weight women with polycystic ovary syndrome. Eur J Intern Med (2008) 0.85
Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact on metabolism and fertility. Endocrine (2013) 0.85
Round-headed spermatozoa in semen specimens from fertile and subfertile men. J Reprod Med (2002) 0.84
Serum luteinizing hormone levels are markedly increased and significantly correlated with Delta 4-androstenedione levels in lean women with polycystic ovary syndrome. Fertil Steril (2005) 0.84
The gonadotropin-releasing hormone (GnRH)-1 gene, the GnRH receptor gene, and their promoters in patients with idiopathic hypogonadotropic hypogonadism with or without resistance to GnRH action. Fertil Steril (2005) 0.84
The role of orlistat combined with lifestyle changes in the management of overweight and obese patients with polycystic ovary syndrome. Clin Endocrinol (Oxf) (2013) 0.84
Oxidised low-density lipoprotein concentration - early marker of an altered lipid metabolism in young women with PCOS. Eur J Endocrinol (2006) 0.83
Cross-sectional analysis of the effects of age on the hormonal, metabolic, and ultrasonographic features and the prevalence of the different phenotypes of polycystic ovary syndrome. Fertil Steril (2011) 0.83
The guidelines issued by the European Society for Human Reproduction and Embryology and the American Society for Reproductive Medicine regarding the induction of ovulation with metformin in patients with the polycystic ovary syndrome potentially require reconsideration. Hormones (Athens) (2013) 0.83
Plasma metastin levels are negatively correlated with insulin resistance and free androgens in women with polycystic ovary syndrome. Fertil Steril (2006) 0.83
Resistin levels in hyperthyroid patients before and after restoration of thyroid function: relationship with body weight and body composition. Eur J Endocrinol (2005) 0.83
Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome. Metabolism (2007) 0.83
Function of the hypothalamic-pituitary-gonadal axis in long-term survivors of hematopoietic stem cell transplantation for hematological diseases. Gynecol Endocrinol (2005) 0.83
The effect of prolonged aerobic exercise on serum adipokine levels during an ultra-marathon endurance race. Hormones (Athens) (2013) 0.83
Association of the Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma2 with decreased basic metabolic rate in women with polycystic ovary syndrome. Eur J Endocrinol (2009) 0.83
Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) (2007) 0.83
Menstrual function in sports. Hormones (Athens) (2011) 0.82
Plasma plasminogen activator inhibitor-1 levels in the different phenotypes of the polycystic ovary syndrome. Endocr J (2011) 0.82
Association of estrogen receptor alpha (ERα) gene polymorphisms with endometrial thickness and lipid profile in women with breast cancer treated with aromatase inhibitors. Gynecol Endocrinol (2012) 0.82
Study of association of IRS-1 and IRS-2 genes polymorphisms with clinical and metabolic features in women with polycystic ovary syndrome. Is there an impact? Gynecol Endocrinol (2010) 0.81
Epidural catheter colonization is not associated with infection. Surg Infect (Larchmt) (2002) 0.81
A polymorphism in the resistin gene promoter is associated with body mass index in women with polycystic ovary syndrome. Fertil Steril (2004) 0.80
Association between menstrual cycle irregularities and endocrine and metabolic characteristics of the polycystic ovary syndrome. Eur J Endocrinol (2013) 0.80
The effects of obesity and polycystic ovary syndrome on serum lipocalin-2 levels: a cross-sectional study. Reprod Biol Endocrinol (2010) 0.80
Delayed but normally progressed puberty is more pronounced in artistic compared with rhythmic elite gymnasts due to the intensity of training. J Clin Endocrinol Metab (2005) 0.80
The effect of selective estrogen receptor modulator administration on the hypothalamic-pituitary-testicular axis in men with idiopathic oligozoospermia. Fertil Steril (2008) 0.80
Hyperreninemia characterizing women with polycystic ovary syndrome improves after metformin therapy. Kidney Blood Press Res (2009) 0.80
The influence of intensive physical exercise on bone acquisition in adolescent elite female and male artistic gymnasts. J Clin Endocrinol Metab (2004) 0.80
Early microvascular and macrovascular dysfunction is not accompanied by structural arterial injury in polycystic ovary syndrome. Hormones (Athens) (2006) 0.80
Serum anti-Müllerian hormone (AMH) levels are differentially modulated by both serum gonadotropins and not only by serum follicle stimulating hormone (FSH) levels. Med Hypotheses (2011) 0.79
Infertility treatment in polycystic ovary syndrome: lifestyle interventions, medications and surgery. Front Horm Res (2012) 0.79
Diet, physical exercise and Orlistat administration increase serum anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome (PCOS). Gynecol Endocrinol (2012) 0.79
Increased frequency of the DI genotype of the angiotensin-I converting enzyme and association of the II genotype with insulin resistance in polycystic ovary syndrome. Eur J Endocrinol (2012) 0.79
Comparison of markers of insulin resistance and circulating androgens between women with polycystic ovary syndrome and women with metabolic syndrome. Hum Reprod (2013) 0.79
Adequacy of saliva 17-hydroxyprogesterone determination using various collection methods. Steroids (2006) 0.79
Prevalence of metabolic syndrome in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) (2013) 0.79
Increased frequency of the anti-mullerian-inhibiting hormone receptor 2 (AMHR2) 482 A>G polymorphism in women with polycystic ovary syndrome: relationship to luteinizing hormone levels. J Clin Endocrinol Metab (2013) 0.79
Hyperthyrotropinemia during iodide administration in normal children and in children born with neonatal transient hypothyroidism. J Clin Endocrinol Metab (2003) 0.79
Semen analysis by electron and fluorescence microscopy in a case of partial hydatidiform mole reveals a high incidence of abnormal morphology, diploidy, and tetraploidy. Fertil Steril (2011) 0.79
Associations of menstrual cycle irregularities with age, obesity and phenotype in patients with polycystic ovary syndrome. Hormones (Athens) (2015) 0.78
Prevalence and impact of hyperandrogenemia in 1,218 women with polycystic ovary syndrome. Endocrine (2014) 0.78
The clinical significance and primary determinants of hirsutism in patients with polycystic ovary syndrome. Eur J Endocrinol (2013) 0.78
Indices of insulin sensitivity, beta cell function and serum proinsulin levels in the polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol (2006) 0.78
The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome. Atherosclerosis (2007) 0.78
Kallmann's syndrome and schizophrenia. Int J Psychiatry Med (2004) 0.78
Plasma von Willebrand factor antigen levels are elevated in the classic phenotypes of polycystic ovary syndrome. Hormones (Athens) (2012) 0.78
Obesity and insulin resistance increase plasma viscosity in young women with polycystic ovary syndrome. Gynecol Endocrinol (2009) 0.78
Decreased active, total and altered active to total ghrelin ratio in normal weight women with the more severe form of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol (2010) 0.77
Serum AMH, FSH, and LH levels in PCOS. Fertil Steril (2010) 0.77
Association of the 17-hydroxysteroid dehydrogenase type 5 gene polymorphism (-71A/G HSD17B5 SNP) with hyperandrogenemia in polycystic ovary syndrome (PCOS). Fertil Steril (2008) 0.77
Increased plasma viscosity in young women with polycystic ovary syndrome using an oral contraceptive containing 35 μg ethinyl estradiol and 2 mg cyproterone acetate. Gynecol Endocrinol (2011) 0.77
Differential effects of unopposed versus opposed hormone therapy, tibolone, and raloxifene on substance p levels. Fertil Steril (2003) 0.77